BNGO — BioNano Genomics Cashflow Statement
0.000.00%
Last trade - 00:00
- $34.87m
- $19.76m
- $36.12m
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -29.8 | -41.1 | -72.4 | -133 | -232 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 4.13 | 4.75 | 10.6 | 24.8 | 90.9 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -4.97 | -3.44 | -7.65 | -28.6 | 2.48 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -29.5 | -38.3 | -71.9 | -125 | -125 |
Capital Expenditures | -0.061 | 0 | -0.822 | -2.41 | -1.69 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | -2.45 | -277 | 85.2 | 25.8 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.061 | -2.45 | -278 | 82.8 | 24.2 |
Financing Cash Flow Items | 0.142 | -2 | -1.7 | -0.428 | -14.9 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 30.4 | 61.9 | 336 | 23 | 114 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.789 | 21.1 | -13.9 | -19.1 | 12.9 |